Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts cut targets for AMBQ, TYRA, NVDA, HUBB and CAN; raised CARL and RIOT targets, while downgrading NVDA and RIOT.
Stocks · News reference
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Corporate Progress
Tyra Biosciences announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs, including initial Phase 2 SURF302 results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57
Tyra Biosciences Q3 EPS $(0.74) Misses $(0.69) Estimate
8-K filing — Tyra Biosciences, Inc. (TYRA)
Filed: 2026-11-10 AccNo: 0001193125-26-454474 Size: 817 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Tyra Biosciences Announces Participation in Upcoming Investor Conferences
Tyra Biosciences, Inc. announced its scheduled participation in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies Global Healthcare Conference in November 2026.
Tyra Biosciences, Inc. Schedules Third Quarter 2026 Earnings Announcement
Tyra Biosciences, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 11, 2026.